"Hospitals in the U.S. continue to make progress in the fight against central line-associated bloodstream infections and some surgical site infections, according to a report issued today by the Centers for Disease Control and Prevention (CDC). "...
- Clinician Information:
Tobramycin Injection Side Effects Center
Medical Editor: John P. Cunha, DO, FACOEP
Tobramycin for Injection is an antibiotic used to treat serious bacterial infections. This medication is available in generic form. Common side effects include dizziness, vertigo, ringing in the ears, kidney problems, anemia, fever, rash, itching, nausea, vomiting, diarrhea, headache, lethargy, pain at the injection site, and confusion.
The dose of Tobramycin for Injection is based on the patient's body weight. Tobramycin for Injection may interact with other drugs. Tell your doctor all medications and supplements you use. Tobramycin for Injection should not be used during pregnancy. It may harm a fetus. Consult your doctor before breastfeeding.
Our Tobramycin for Injection Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
What is Prescribing information?
The FDA package insert formatted in easy-to-find categories for health professionals and clinicians.
Tobramycin Injection FDA Prescribing Information: Side Effects
Neurotoxicity - Adverse effects on both the vestibular and auditory branches of the eighth nerve have been noted, especially in patients receiving high doses or prolonged therapy, in those given previous courses of therapy with an ototoxin, and in cases of dehydration. Symptoms include dizziness, vertigo, tinnitus, roaring in the ears, and hearing loss. Hearing loss is usually irreversible and is manifested initially by diminution of high-tone acuity. Tobramycin and gentamicin sulfates closely parallel each other in regard to ototoxic potential.
Nephrotoxicity - Renal function changes, as shown by rising BUN, NPN, and serum creatinine and by oliguria, cylindruria, and increased proteinuria, have been reported, especially in patients with a history of renal impairment who are treated for longer periods or with higher doses than those recommended. Adverse renal effects can occur in patients with initially normal renal function.
Clinical studies and studies in experimental animals have been conducted to compare the nephrotoxic potential of tobramycin and gentamicin. In some of the clinical studies and in the animal studies, tobramycin caused nephrotoxicity significantly less frequently than gentamicin. In some other clinical studies, no significant difference in the incidence of nephrotoxicity between tobramycin and gentamicin was found.
Other reported adverse reactions possibly related to tobramycin include anemia, granulocytopenia, and thrombocytopenia; and fever, rash, exfoliative dermatitis, itching, urticaria, nausea, vomiting, diarrhea, headache, lethargy, pain at the injection site, mental confusion, and disorientation. Laboratory abnormalities possibly related to tobramycin include increased serum transaminases (AST, ALT); increased serum LDH and bilirubin; decreased serum calcium, magnesium, sodium, and potassium; and leukopenia, leukocytosis, and eosinophilia.
Read the entire FDA prescribing information for Tobramycin Injection (Tobramycin Injection) »
Additional Tobramycin Injection Information
Report Problems to the Food and Drug Administration
Find out what women really need.